ProMIS reports Q1 2023 results, FDA clears IND for Alzheimer's candidate PMN310

ProMIS Neurosciences Inc.

2023-Q1 EPS reported -$0.58

FDA cleared IND for lead therapeutic candidate PMN310 for Alzheimer's disease; phase 1 enabling activities underway.
Cash and cash equivalents of $3.3M as of March 31, 2023, down from $5.9M at December 31, 2022.
Net loss of $5.0M for Q1 2023 compared to $2.1M in Q1 2022, driven by increased R&D spending on PMN310.
R&D expenses rose to $3.5M from $1.9M YoY, primarily for drug product manufacturing and IND filing costs.
Preclinical data presented at AD/PD and AAN conferences showing PMN310 selectivity and memory protection in AD models.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ProMIS Neurosciences Inc. reported the quarter ended March 31, 2023 results: net income $5.0 million.

Period: the quarter ended March 31, 2023
Net income: $5.0 million
Result: reported results

Exact text from the filing

Net loss was $5.0 million for the quarter ended March 31, 2023, compared to $2.1 million for the same period in 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-009944

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.